Hemab Therapeutics Inc. Common Stock
COAG | NASDAQ
$41.38
+$0.96 (+2.38%)
At close: Oct 30, 2026, 3:59 PM ET
$41.66
+$0.28 (+0.68%)
After-hours:
Oct 30, 2026, 7:48 PM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 |
|---|---|
Revenue | n/a |
Cost of Revenue | n/a |
Gross Profit | n/a |
Operating Income | -70.12M |
Interest Income | 1.97M |
Pretax Income | -64.14M |
Net Income | -63.91M |
Selling & General & Admin | 10.49M |
Research & Development | 59.63M |
Other Expenses | n/a |
Operating Expenses | 70.12M |
Interest Expense | n/a |
Selling & Marketing Expenses | n/a |
Cost & Expenses | 70.12M |
Income Tax Expense | -227K |
Shares Outstanding (Basic) | 27.44M |
Shares Outstanding (Diluted) | 27.44M |
EPS (Basic) | -2.33 |
EPS (Diluted) | -2.33 |
EBITDA | -69.82M |
EBIT | -70.12M |
Depreciation & Amortization | 304K |
Add to Watchlist
Select watchlists to add or remove COAG